Revvity (NYSE:RVTY) Price Target Raised to $120.00

Revvity (NYSE:RVTY) had its target price lifted by TD Cowen from $115.00 to $120.00 in a research note published on Wednesday morning,Benzinga reports. TD Cowen currently has a buy rating on the stock.

Other analysts also recently issued research reports about the stock. Stifel Nicolaus dropped their target price on shares of Revvity from $110.00 to $100.00 and set a “hold” rating for the company in a report on Wednesday. Wells Fargo & Company raised their price target on Revvity from $107.00 to $110.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 3rd. Jefferies Financial Group lifted their price objective on Revvity from $100.00 to $105.00 and gave the company a “hold” rating in a research note on Monday, February 2nd. Weiss Ratings downgraded Revvity from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, March 18th. Finally, JPMorgan Chase & Co. decreased their target price on Revvity from $105.00 to $96.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 31st. Four equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Revvity currently has an average rating of “Hold” and a consensus target price of $107.73.

Revvity Trading Up 2.5%

NYSE RVTY opened at $101.32 on Wednesday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.72 and a quick ratio of 1.40. The stock has a market capitalization of $11.33 billion, a P/E ratio of 48.48, a PEG ratio of 2.15 and a beta of 1.05. The firm’s 50-day moving average is $90.30 and its two-hundred day moving average is $96.90. Revvity has a 12 month low of $81.22 and a 12 month high of $118.30.

Revvity (NYSE:RVTY) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. The business had revenue of $711.12 million during the quarter, compared to analysts’ expectations of $704.07 million. Revvity had a net margin of 8.26% and a return on equity of 8.00%. The business’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same period last year, the business earned $1.01 earnings per share. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. On average, sell-side analysts anticipate that Revvity will post 5.29 earnings per share for the current year.

Revvity Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 7th. Shareholders of record on Friday, July 17th will be paid a $0.07 dividend. The ex-dividend date is Friday, July 17th. This represents a $0.28 annualized dividend and a dividend yield of 0.3%. Revvity’s payout ratio is 13.40%.

Institutional Trading of Revvity

A number of large investors have recently modified their holdings of the stock. New York Life Investment Management LLC raised its stake in Revvity by 72.7% in the third quarter. New York Life Investment Management LLC now owns 27,520 shares of the company’s stock valued at $2,412,000 after buying an additional 11,583 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Revvity by 15.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 511,360 shares of the company’s stock worth $44,821,000 after acquiring an additional 67,662 shares in the last quarter. Tudor Investment Corp ET AL acquired a new position in shares of Revvity during the 3rd quarter worth about $15,128,000. Campbell & CO Investment Adviser LLC purchased a new position in shares of Revvity in the 3rd quarter valued at about $905,000. Finally, First National Bank of Omaha purchased a new position in shares of Revvity in the 3rd quarter valued at about $6,432,000. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.